Fox Chase Cancer Center News

PHILADELPHIA (December 20, 2019) – The Fox Chase-Temple University Hospital Bone Marrow Transplant Program has been recognized by the CIBMTR for performing better than expected for successful transplant procedures. Fox Chase was the only adult treatment center in the tristate area to achieve this distinction.

PHILADELPHIA (Dec. 18, 2019)—Temple University and Thomas Jefferson University today announced that the two institutions have entered into a binding Definitive Agreement for the acquisition by Jefferson of Fox Chase Cancer Center (FCCC), as well as Temple’s Bone Marrow Transplant program.

PHILADELPHIA (December 17, 2019) – Elizabeth Plimack, MD, MS, professor and chief of the Division of Genitourinary Medical Oncology at Fox Chase Cancer Center, will begin her four-year term in June 2020 and is eager to be representing Fox Chase as she works to encourage collaboration and methods of sharing information in oncology.

PHILADELPHIA (December 16, 2019) – New research from Fox Chase Cancer Center has set the framework for gene therapy as a possible treatment for human cystathionine beta-synthase deficiency, the most common inborn error of metabolism found in children. “We showed that the DNA we treated was expressed in the liver and could reverse the phenotypes we observed in mice with CBS deficiency.”

PHILADELPHIA (December 16, 2019) – Almost one-third of patients with clear cell renal cell carcinoma (ccRCC) who underwent surgery for their cancer at Fox Chase Cancer Center were found to have a loss of the whole or a segment of chromosome 9. This was associated with several adverse disease characteristics and outcomes.

PHILADELPHIA (December 13, 2019) –  For the past 10 years, Fox Chase Cancer Center has served as one of six regional GMaP hubs and will be able to continue and expand its role with a new $500,000 grant from the National Cancer Institute.

PHILADELPHIA (December 13, 2019) – Robert Uzzo and colleagues found that type-2 papillary renal cell carcinomas were more likely to have lower pre-contrast attenuation than type-1 tumors.

PHILADELPHIA (December 11, 2019) – New research indicates that BRCA1 gene rearrangements are responsible for generating partially active proteins that drive the development of resistance to PARP inhibitors.